BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:07 PM
 | 
Jan 08, 2008
 |  BC Extra  |  Company News

Ophthotech in-licenses volociximab for ophthalmic uses

Biogen Idec (NASDAQ:BIIB) and PDL (NASDAQ:PDLI) granted Ophthotech (Princeton, N.J.) an exclusive, worldwide license to develop and commercialize volociximab (M200) for ophthalmic indications....

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >